Características clínico-epidemiológicas de pacientes con síndrome de Guillain-Barré y COVID-19: Revisión Sistemática

Descripción del Articulo

There is evidence that SARS-CoV-2, the COVID-19 virus, is related as a predisposing factor or as a trigger with direct demyelinating pathophysiology in Guillain Barre Syndrome (GBS). Objective: To describe the clinical-epidemiological characteristics of patients with Guillain- Barre syndrome and COV...

Descripción completa

Detalles Bibliográficos
Autor: Merino Ramírez, Junior Sleyter
Formato: tesis de grado
Fecha de Publicación:2022
Institución:Universidad Nacional de Trujillo
Repositorio:UNITRU-Tesis
Lenguaje:español
OAI Identifier:oai:dspace.unitru.edu.pe:20.500.14414/18478
Enlace del recurso:https://hdl.handle.net/20.500.14414/18478
Nivel de acceso:acceso abierto
Materia:Síndrome de Guillain Barré,
COVID-19
SARS-CoV-2
Polirradiculoneuropatía Aguda Inflamatoria
Descripción
Sumario:There is evidence that SARS-CoV-2, the COVID-19 virus, is related as a predisposing factor or as a trigger with direct demyelinating pathophysiology in Guillain Barre Syndrome (GBS). Objective: To describe the clinical-epidemiological characteristics of patients with Guillain- Barre syndrome and COVID-19. Methods: Systematic review-type secondary research without meta-analysis (n=106), selected from 88 articles, where the clinical-epidemiological data were extracted, generating a database, percentages, averages, minimum and maximum values were calculated for the preparation of tables. Results: It occurred mainly in men, in patients with an average age of 52.94 years, it occurred within the first 10 days in 45.28%, the form of ascending presentation was the most common with 63.21%, as well as the AIDP variant in 55.66%, 29.25% required mechanical ventilation, with the most common comorbidity being hypertension (28.72%) and the most used treatment immunoglobulin IV (86.79%). Conclusion: GBS in COVID-19 occurs mainly in men, over 50 years of age, with the ascending, demyelinating variant being the most frequent, the use of immunoglobulin being the most frequent, and having a high recovery rate.
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).